blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3763717

EP3763717 - PYRIDO[4,3-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS [Right-click to bookmark this link]
Former [2021/02]PYRIDO[4,3-D][1,3]OXAZIN-2-ONE AND PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS
[2021/46]
StatusNo opposition filed within time limit
Status updated on  12.01.2024
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  03.02.2023
FormerGrant of patent is intended
Status updated on  20.09.2022
FormerRequest for examination was made
Status updated on  10.08.2022
FormerGrant of patent is intended
Status updated on  07.04.2022
FormerRequest for examination was made
Status updated on  23.03.2022
FormerGrant of patent is intended
Status updated on  16.11.2021
FormerRequest for examination was made
Status updated on  16.07.2021
FormerThe application has been published
Status updated on  11.12.2020
Most recent event   Tooltip30.08.2024Lapse of the patent in a contracting state
New state(s): LU, MC		published on 02.10.2024 [2024/40]
Applicant(s)For all designated states
ELI LILLY AND CO.
Lilly Corporate Center
Indianapolis, IN 46285 / US
[2021/02]
Inventor(s)01 / BAUER, Renato Alejandro
c/o Eli Lilly and Company
P.O. Box 6288
Indianapolis, Indiana 46206-6288 / US
02 / BOULET, Serge Louis
c/o Eli Lilly and Company
P.O. Box 6288
Indianapolis, Indiana 46206-6288 / US
03 / BURKHOLDER, Timothy Paul
c/o Eli Lilly and Company
P.O. Box 6288
Indianapolis, Indiana 46206-6288 / US
04 / GILMOUR, Raymond
c/o Eli Lilly and Company
P.O. Box 6288
Indianapolis, Indiana 46206-6288 / US
05 / HAHN, Patric James
c/o Eli Lilly and Company
P.O. Box 6288
Indianapolis, Indiana 46206-6288 / US
06 / RANKOVIC, Zoran
c/o Eli Lilly and Company
P.O. Box 6288
Indianapolis, Indiana 46206-6288 / US
 [2021/02]
Representative(s)Ingham, Stephen Howard
Eli Lilly and Company Limited
8 Arlington Square West Downshire Way
Bracknell, Berkshire RG12 1PU / GB
[2021/02]
Application number, filing date20189241.108.12.2017
[2021/02]
Priority number, dateUS201662435283P16.12.2016         Original published format: US 201662435283 P
[2021/02]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3763717
Date:13.01.2021
Language:EN
[2021/02]
Type: B1 Patent specification 
No.:EP3763717
Date:08.03.2023
Language:EN
[2023/10]
Search report(s)(Supplementary) European search report - dispatched on:EP15.10.2020
ClassificationIPC:C07D498/04, A61P35/00, A61K31/5365
[2021/02]
CPC:
C07D498/04 (EP,CN,EA,IL,KR,US); A61P35/00 (EP,CN,EA,IL,KR); A61K31/5365 (IL,KR);
A61P35/02 (CN,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/33]
Former [2021/02]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBA13.07.2021
ME13.07.2021
Validation statesMA13.07.2021
MD13.07.2021
TitleGerman:PYRIDO[4,3-D][1,3]OXAZIN-2-ON-DERIVATE ALS INHIBITOREN DER MUTIERTEN IDH1 UND IDH2 PROTEINE[2021/46]
English:PYRIDO[4,3-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS[2021/46]
French:DÉRIVÉS DE PYRIDO[4,3-D][1,3]OXAZIN-2-ONE EN TANT QU'INHIBITEURS DE LA FORME MUTÉE DES PROTÉINES IDH1 ET IDH2[2021/46]
Former [2021/02]PYRIDO[4,3-D][1,3]OXAZIN-2-ON- UND PYRIMIDO[4,5-D][1,3]OXAZIN-2-ON-DERIVATE ALS INHIBITOREN DER MUTIERTEN IDH1 UND IDH2 PROTEINE
Former [2021/02]PYRIDO[4,3-D][1,3]OXAZIN-2-ONE AND PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS
Former [2021/02]DÉRIVÉS DE PYRIDO[4,3-D][1,3]OXAZIN-2-ONE ET DE PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE EN TANT QU'INHIBITEURS DE LA FORME MUTÉE DES PROTÉINES IDH1 ET IDH2
Examination procedure01.07.2021Amendment by applicant (claims and/or description)
13.07.2021Examination requested  [2021/33]
13.07.2021Date on which the examining division has become responsible
17.11.2021Communication of intention to grant the patent
17.03.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
08.04.2022Communication of intention to grant the patent
10.08.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
21.09.2022Communication of intention to grant the patent
20.01.2023Fee for grant paid
20.01.2023Fee for publishing/printing paid
20.01.2023Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP17822882.1  / EP3555105
Opposition(s)11.12.2023No opposition filed within time limit [2024/07]
Fees paidRenewal fee
03.12.2020Renewal fee patent year 03
11.01.2021Renewal fee patent year 04
03.01.2022Renewal fee patent year 05
02.01.2023Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
MC08.03.2023
NL08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
LU08.12.2023
[2024/40]
Former [2024/10]AT08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
Former [2023/50]AT08.03.2023
CZ08.03.2023
EE08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
Former [2023/49]AT08.03.2023
CZ08.03.2023
EE08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
PT10.07.2023
Former [2023/48]AT08.03.2023
EE08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
RS08.03.2023
SE08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
PT10.07.2023
Former [2023/46]FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
RS08.03.2023
SE08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
PT10.07.2023
Former [2023/38]FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
RS08.03.2023
SE08.03.2023
NO08.06.2023
GR09.06.2023
Former [2023/37]FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
RS08.03.2023
SE08.03.2023
NO08.06.2023
GR09.06.2023
Former [2023/36]FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
RS08.03.2023
SE08.03.2023
NO08.06.2023
Former [2023/35]HR08.03.2023
LT08.03.2023
RS08.03.2023
NO08.06.2023
Former [2023/34]LT08.03.2023
RS08.03.2023
Former [2023/33]LT08.03.2023
Documents cited:Search[A]WO2013046136  (NOVARTIS AG [CH], et al);
 [A]WO2016171755  (FORMA THERAPEUTICS INC [US]);
 [ADP]WO2017019429  (LILLY CO ELI [US])
by applicantWO2016US43264
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.